Perspective Therapeutics (CATX) Other Non-Current Assets (2011 - 2026)
Perspective Therapeutics (CATX) reported Other Non-Current Assets of $490000.0 for Q1 2026, up 0.82% sequentially from $486000.0 in Q4 2025.
Perspective Therapeutics (CATX) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 16 years of Other Non-Current Assets data on file, last reported at $490000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets changed N/A year-over-year to $490000.0; the trailing twelve-month figure through Mar 2026 stood at $490000.0 (changed N/A YoY), and the FY2025 full-year result was $486000.0, up 20.0% from the prior year.
- Other Non-Current Assets climbed to $490000.0 in Q1 2026, from $486000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $490000.0 in Q1 2026 to a low of $175000.0 in Q4 2022.
- A 5-year average of $289200.0 and a median of $182000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets surged 178.29% in 2023 and declined 16.84% in 2024, its largest moves.
- Tracing CATX's Other Non-Current Assets over 5 years: stood at $175000.0 in 2022, then surged by 178.29% to $487000.0 in 2023, then retreated by 16.84% to $405000.0 in 2024, then climbed by 20.0% to $486000.0 in 2025, then advanced by 0.82% to $490000.0 in 2026.
- Business Quant data shows CATX's Other Non-Current Assets at $490000.0 in Q1 2026, $486000.0 in Q4 2025, and $438000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 4.15 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 2.05 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 285.90 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 828.89 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.25 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 164.00 Mn |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | 490,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 490,000.00 |
| Dec 31, 2025 | 486,000.00 |
| Sep 30, 2025 | 438,000.00 |
| Jun 30, 2025 | 401,000.00 |
| Dec 31, 2024 | 405,000.00 |
| Jun 30, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 487,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 182,000.00 |
| Mar 31, 2023 | 182,000.00 |
| Dec 31, 2022 | 175,000.00 |
| Sep 30, 2022 | 182,000.00 |
| Jun 30, 2022 | 182,000.00 |
| Mar 31, 2022 | 182,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 182,000.00 |
| Jun 30, 2021 | 130,000.00 |
| Mar 31, 2021 | 182,000.00 |
| Dec 31, 2020 | 182,000.00 |